Pharmacokinetic interaction between linagliptin and tadalafil in healthy Egyptian males using a novel LC–MS method / Sara S Mourad, Eman I El-Kimary, Magda A Barary, Dalia A Hamdy
Aim:Assessment of pharmacokinetic interaction between linagliptin (LNG) and tadalafil (TDL) in healthy males.Methods:First, a novel LC–MS method was developed; second, a Phase IV, open-label, cross-over study was performed. Volunteers took single 20-mg TDL dose on day 1 followed by wash out period of 2 weeks then multiple oral dosing of 5-mg/day LNG for 13 days. On day 13, volunteers were co-administered 20-mg TDL.Results:LNG and TDL single doses did not affect QTc interval. Smoking did not alter pharmacokinetics/pharmacodynamics of LNG and TDL. Co-administration of LNG with TDL resulted in TDL longer time to reach maximum plasma concentration (Tmax), decreased oral clearance (Cl/F) and oral volume of distribution (Vd/F), increased its maximum plasma concentration (Cmax), area under concentration-time curve (AUC), muscle pain and QTc prolongation.Conclusion:LNG and TDL co-administration warrants monitoring and/or TDL dose adjustment. Aim: Methods: Results: max max Conclusion.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Bioanalysis - 11(2019), 14, Seite 1321- |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mourad, Sara S [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Umfang: |
1 Online-Ressource (16 p) |
|---|
| doi: |
10.4155/bio-2018-0097 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL001038974 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL001038974 | ||
| 003 | DE-627 | ||
| 005 | 20230430081454.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210608s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4155/bio-2018-0097 |2 doi | |
| 035 | |a (DE-627)KFL001038974 | ||
| 035 | |a (KFL)prod_FICIBQ_10.4155/bio-2018-0097 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Mourad, Sara S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pharmacokinetic interaction between linagliptin and tadalafil in healthy Egyptian males using a novel LC–MS method |c Sara S Mourad, Eman I El-Kimary, Magda A Barary, Dalia A Hamdy |
| 264 | 1 | |c 2019 | |
| 300 | |a 1 Online-Ressource (16 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Aim:Assessment of pharmacokinetic interaction between linagliptin (LNG) and tadalafil (TDL) in healthy males.Methods:First, a novel LC–MS method was developed; second, a Phase IV, open-label, cross-over study was performed. Volunteers took single 20-mg TDL dose on day 1 followed by wash out period of 2 weeks then multiple oral dosing of 5-mg/day LNG for 13 days. On day 13, volunteers were co-administered 20-mg TDL.Results:LNG and TDL single doses did not affect QTc interval. Smoking did not alter pharmacokinetics/pharmacodynamics of LNG and TDL. Co-administration of LNG with TDL resulted in TDL longer time to reach maximum plasma concentration (Tmax), decreased oral clearance (Cl/F) and oral volume of distribution (Vd/F), increased its maximum plasma concentration (Cmax), area under concentration-time curve (AUC), muscle pain and QTc prolongation.Conclusion:LNG and TDL co-administration warrants monitoring and/or TDL dose adjustment. Aim: Methods: Results: max max Conclusion | ||
| 700 | 1 | |a El-Kimary, Eman I |e verfasserin |4 aut | |
| 700 | 1 | |a Barary, Magda A |e verfasserin |4 aut | |
| 700 | 1 | |a Hamdy, Dalia A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Bioanalysis |d London : Future Science, 2009 |g 11(2019), 14, Seite 1321- |h Online-Ressource |w (DE-627)KFL000038172 |w (DE-600)2571813-7 |w (DE-576)398101434 |x 1757-6199 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2019 |g number:14 |g pages:1321- |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/future-medicine-ejournals-pharmazie/doi.org/10.4155/bio-2018-0097 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 935 | |i IMPORT_0628_prod_FICIBQ_03 | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2019 |e 14 |h 1321- | ||